litlas
Log inCreate account

Cloud P. Paweletz

Active 2000–2025

108
Papers
20,781
Citations
71
h-index
104
i10-index

Citations

Citations per year for Cloud P. Paweletz2000: 12 citations2001: 31 citations2002: 86 citations2003: 96 citations2004: 121 citations2005: 99 citations2006: 84 citations2007: 63 citations2008: 55 citations2009: 38 citations2010: 68 citations2011: 53 citations2012: 44 citations2013: 41 citations2014: 50 citations2015: 71 citations2016: 172 citations2017: 222 citations2018: 291 citations2019: 932 citations2020: 1,113 citations2021: 1,286 citations2022: 1,070 citations2023: 902 citations2024: 1,365 citations2025: 789 citations2026: 24 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,560 citing papers, 29.3% of this breakdownChina: 1,803 citing papers, 14.9% of this breakdownUnited Kingdom: 585 citing papers, 4.8% of this breakdownItaly: 572 citing papers, 4.7% of this breakdownGermany: 541 citing papers, 4.5% of this breakdownFrance: 474 citing papers, 3.9% of this breakdownJapan: 426 citing papers, 3.5% of this breakdownSpain: 376 citing papers, 3.1% of this breakdownAustralia: 317 citing papers, 2.6% of this breakdownCanada: 303 citing papers, 2.5% of this breakdownNetherlands: 295 citing papers, 2.4% of this breakdownSouth Korea: 288 citing papers, 2.4% of this breakdown
0%29.3%Other 21.4%

Institutions

Fields

  • Medicine49.6%
  • Biochemistry, Genetics and Molecular Biology32.8%
  • Immunology and Microbiology11.1%
  • Chemistry2.8%
  • Engineering2%
  • Agricultural and Biological Sciences0.3%
  • Other1.4%

Topics

  • Lung Cancer Treatments and Mutations7.3%
  • Cancer Genomics and Diagnostics6.9%
  • Cancer Immunotherapy and Biomarkers6.6%
  • CAR-T cell therapy research3.1%
  • Immunotherapy and Immune Responses3%
  • Immune Cell Function and Interaction2.9%
  • Other70.2%

Coauthors

All papers

Open in search
  1. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

    Authors: Moshe Sade-Feldman, Keren Yizhak, Stacey L. Bjorgaard, John P. Ray, Carl G. de Boer, Russell W. Jenkins, David Lieb, Jonathan Chen, Dennie T. Frederick, Michal Barzily-Rokni, Samuel S. Freeman, Alexandre Reuben, Paul Hoover, Alexandra–Chloé Villani, Elena V. Ivanova, Andrew Portell, Patrick H. Lizotte, Amir Reza Aref, Jean-Pierre Eliane, Marc R. Hammond, Hans Vitzthum, Shauna Blackmon, Bo Li, Vancheswaran Gopalakrishnan, Sangeetha M. Reddy, Zachary A. Cooper, Cloud P. Paweletz, David A. Barbie, Anat Stemmer‐Rachamimov, Keith T. Flaherty, Jennifer A. Wargo, Genevieve M. Boland, Ryan J. Sullivan, Gad Getz, Nir Hacohen - Cell 2018 cited by 2,103

  2. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

    Authors: Rona Yaeger, Jared Weiss, Meredith Pelster, Alexander I. Spira, Minal Barve, Sai‐Hong Ignatius Ou, Ticiana Leal, Tanios Bekaii‐Saab, Cloud P. Paweletz, Grace A. Heavey, James G. Christensen, Karen Velastegui, Thian Kheoh, Hirak Der‐Torossian, Samuel J. Klempner - New England Journal of Medicine 2022 cited by 485

  3. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway

    Authors: Kari J. Kurppa, Yao Liu, Ciric To, Tinghu Zhang, Mengyang Fan, Amir Vajdi, Erik H. Knelson, Yingtian Xie, Klothilda Lim, Paloma Cejas, Andrew Portell, Patrick H. Lizotte, Scott B. Ficarro, Shuai Li, Ting Chen, Heidi M. Haikala, Haiyun Wang, Magda Bahcall, Yang Gao, Sophia Z. Shalhout, Steffen Boettcher, Bo Hee Shin, Tran C. Thai, Margaret K. Wilkens, Michelle Tillgren, Mierzhati Mushajiang, Man Xu, Jihyun Choi, Arrien A. Bertram, Benjamin L. Ebert, Rameen Beroukhim, Pratiti Bandopadhayay, Mark M. Awad, Prafulla C. Gokhale, Paul T. Kirschmeier, Jarrod A. Marto, Fernando D. Camargo, Rizwan Haq, Cloud P. Paweletz, Kwok‐Kin Wong, David A. Barbie, Henry W. Long, Nathanael S. Gray, Pasi A. Jänne - Cancer Cell 2020 cited by 472

  4. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

    Authors: Kenneth S. Thress, Cloud P. Paweletz, Enriqueta Felip, Byoung Chul Cho, Daniel Stetson, Brian Dougherty, Zhongwu Lai, Aleksandra Markovets, Ana Vivancos, Yanan Kuang, Dalia Ercan, Sarah E Matthews, Mireille Cantarini, J. Carl Barrett, Pasi A. Jänne, Geoffrey R. Oxnard - Nature Medicine 2015 cited by 1,539

  5. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

    Authors: Russell W. Jenkins, Amir Reza Aref, Patrick H. Lizotte, Elena V. Ivanova, Susanna Stinson, Chensheng W. Zhou, Michaela Bowden, Jiehui Deng, Hongye Liu, Diana Miao, Meng Xiao He, William H. Walker, Gao Zhang, Tian Tian, Chaoran Cheng, Zhi Wei, Sangeetha Palakurthi, Mark Bittinger, Hans Vitzthum, Jong Wook Kim, Ashley A. Merlino, Max M. Quinn, Chandrasekar Venkataramani, Joshua A. Kaplan, Andrew Portell, Prafulla C. Gokhale, Bart Phillips, Alicia Smart, Asaf Rotem, Robert E. Jones, Lauren Keogh, María Anguiano, Lance Stapleton, Zhiheng Jia, Michal Barzily-Rokni, Israel Cañadas, Tran C. Thai, Marc R. Hammond, Raven Vlahos, Eric S. Wang, Hua Zhang, Shuai Li, Glenn J. Hanna, Wei Huang, Mai P. Hoang, Adriano Piris, Jean-Pierre Eliane, Anat Stemmer‐Rachamimov, Lisa Cameron, Mei-Ju Su, Parin Shah, Benjamin Izar, Manisha Thakuria, Nicole R. LeBoeuf, Guilherme Rabinowits, Viswanath Gunda, Sareh Parangi, James M. Cleary, Brian C. Miller, Shunsuke Kitajima, Rohit Thummalapalli, Benchun Miao, Thanh U. Barbie, Vivek Sivathanu, Joshua A. Wong, William G. Richards, Raphael Bueno, Charles H. Yoon, Juan J. Miret, Meenhard Herlyn, Levi A. Garraway, Eliezer M. Van Allen, Gordon J. Freeman, Paul T. Kirschmeier, Jochen H. Lorch, Patrick A. Ott, F. Stephen Hodi, Keith T. Flaherty, Roger D. Kamm, Genevieve M. Boland, Kwok‐Kin Wong, David Dornan, Cloud P. Paweletz, David A. Barbie - Cancer Discovery 2017 cited by 585

  6. CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

    Authors: Jiehui Deng, Eric S. Wang, Russell W. Jenkins, Shuai Li, Ruben Dries, Kathleen Yates, Sandeep Chhabra, Wei Huang, Hongye Liu, Amir Reza Aref, Elena V. Ivanova, Cloud P. Paweletz, Michaela Bowden, Chensheng W. Zhou, Grit S. Herter-Sprie, Jessica A. Sorrentino, John Bisi, Patrick H. Lizotte, Ashley A. Merlino, Max M. Quinn, Lauren E. Bufe, Annan Yang, Y. Zhang, Hua Zhang, Peng Gao, Ting Chen, Megan E. Cavanaugh, Amanda J. Rode, Eric Haines, Patrick J. Roberts, Jay C. Strum, William G. Richards, Jochen H. Lorch, Sareh Parangi, Viswanath Gunda, Genevieve M. Boland, Raphael Bueno, Sangeetha Palakurthi, Gordon J. Freeman, Jerome Ritz, W. Nicholas Haining, Norman E. Sharpless, Haribabu Arthanari, Geoffrey I. Shapiro, David A. Barbie, Nathanael S. Gray, Kwok‐Kin Wong - Cancer Discovery 2017 cited by 781

  7. Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer

    Authors: Shunsuke Kitajima, Elena V. Ivanova, Sujuan Guo, Ryohei Yoshida, Marco Campisi, Shriram K. Sundararaman, Shoichiro Tange, Yoichiro Mitsuishi, Tran C. Thai, Sayuri Masuda, Brandon Piel, Lynette M. Sholl, Paul T. Kirschmeier, Cloud P. Paweletz, Hideo Watanabe, Mamiko Yajima, David A. Barbie - Cancer Discovery 2018 cited by 515

  8. Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity

    Authors: Navin R. Mahadevan, Erik H. Knelson, Jacquelyn O. Wolff, Amir Vajdi, Maria Saigí, Marco Campisi, Deli Hong, Tran C. Thai, Brandon Piel, Saemi Han, Bruce B. Reinhold, Jonathan S. Duke‐Cohan, Michael J. Poitras, Luke J. Taus, Patrick H. Lizotte, Andrew Portell, Victor Quadros, Alison Santucci, Takahiko Murayama, Israel Cañadas, Shunsuke Kitajima, Aoi Akitsu, Maya Fridrikh, Hideo Watanabe, Brendan Reardon, Prafulla C. Gokhale, Cloud P. Paweletz, Mark M. Awad, Eliezer M. Van Allen, Ana Lako, Xitao Wang, Bowen Chen, Fangxin Hong, Lynette M. Sholl, Michael Tolstorukov, Kathleen L. Pfaff, Pasi A. Jänne, Evisa Gjini, Robin Edwards, Scott J. Rodig, Ellis L. Reinherz, Matthew G. Oser, David A. Barbie - Cancer Discovery 2021 cited by 214

  9. Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies

    Authors: Justin I. Odegaard, John J. Vincent, Stefanie Mortimer, James V. Vowles, Bryan C. Ulrich, Kimberly C. Banks, Stephen R. Fairclough, Oliver A. Zill, Marcin Sikora, Reza Bayat Mokhtari, Diana Abdueva, Rebecca J. Nagy, Christine E. Lee, Lesli A. Kiedrowski, Cloud P. Paweletz, Helmy Eltoukhy, Richard B. Lanman, Darya Chudova, AmirAli Talasaz - Clinical Cancer Research 2018 cited by 435

  10. Targeting TBK1 to overcome resistance to cancer immunotherapy

    Authors: Yi Sun, Or‐Yam Revach, Seth Anderson, Emily Kessler, Clara Wolfe, Anne Jenney, Caitlin E. Mills, Emily Robitschek, Thomas Davis, Sarah Kim, Amina Fu, Xiang Ma, Jia Gwee, Payal Tiwari, Peter P. Du, Princy Sindurakar, Jun Tian, Arnav Mehta, Alexis M. Schneider, Keren Yizhak, Moshe Sade-Feldman, Thomas J. LaSalle, Tatyana Sharova, Hongyan Xie, Shuming Liu, William A. Michaud, Rodrigo Saad-Beretta, Kathleen B. Yates, Arvin Iracheta‐Vellve, Johan Spetz, Xingping Qin, Kristopher A. Sarosiek, Gao Zhang, Jong Wook Kim, Mack Y. Su, Angelina M. Cicerchia, Martin Q. Rasmussen, Samuel J. Klempner, Dejan Juric, Sara I. Pai, David M. Miller, Anita Giobbie‐Hurder, Jonathan Chen, Karin Pelka, Dennie T. Frederick, Susanna Stinson, Elena V. Ivanova, Amir Reza Aref, Cloud P. Paweletz, David A. Barbie, Debattama R. Sen, David E. Fisher, Ryan B. Corcoran, Nir Hacohen, Peter K. Sorger, Keith T. Flaherty, Genevieve M. Boland, Robert T. Manguso, Russell W. Jenkins - Nature 2023 cited by 167

  11. Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

    Authors: Geoffrey R. Oxnard, Yuebi Hu, Kathryn F. Mileham, Hatim Husain, Daniel B. Costa, Philip Tracy, Nora Feeney, Lynette M. Sholl, Suzanne E. Dahlberg, Amanda J. Redig, David J. Kwiatkowski, Michael S. Rabin, Cloud P. Paweletz, Kenneth S. Thress, Pasi A. Jänne - JAMA Oncology 2018 cited by 689

  12. Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancer

    Authors: Giacomo Oliveira, Ann Marie Egloff, Alexander B. Afeyan, Jacquelyn O. Wolff, Zexiang Zeng, Rebecca D. Chernock, Liye Zhou, Cameron Messier, Patrick H. Lizotte, Kathleen L. Pfaff, Kari Stromhaug, Livius Penter, Robert I. Haddad, Glenn J. Hanna, Jonathan D. Schoenfeld, Laura A. Goguen, Donald J. Annino, Vickie Y. Jo, Peter Oppelt, Patrik Pipkorn, Ryan S. Jackson, Sidharth V. Puram, Randal C. Paniello, Jason T. Rich, J. C. Webb, José P. Zevallos, Mena Mansour, Jingxin Fu, Gavin P. Dunn, Scott J. Rodig, Jessica Ley, Luc G.T. Morris, Lara Dunn, Cloud P. Paweletz, Dorina Kallogjeri, Jay F. Piccirillo, Douglas R. Adkins, Catherine J. Wu, Ravindra Uppaluri - Science Immunology 2023 cited by 116

  13. Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses

    Authors: Israel Cañadas, Rohit Thummalapalli, Jong Wook Kim, Shunsuke Kitajima, Russell W. Jenkins, Camilla L. Christensen, Marco Campisi, Yanan Kuang, Yanxi Zhang, Evisa Gjini, Gao Zhang, Tian Tian, Debattama R. Sen, Diana Miao, Yu Imamura, Tran C. Thai, Brandon Piel, Hideki Terai, Amir Reza Aref, Timothy Hagan, Shohei Koyama, Masayuki Watanabe, Hideo Baba, Anika E. Adeni, Christine Lydon, Pablo Tamayo, Zhi Wei, Meenhard Herlyn, Thanh U. Barbie, Ravindra Uppaluri, Lynnette Marie Sholl, Ewa Sicińska, Jacob Sands, Scott J. Rodig, Kwok‐Kin Wong, Cloud P. Paweletz, Hideo Watanabe, David A. Barbie - Nature Medicine 2018 cited by 317

  14. TREX1 Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity

    Authors: Tetsuo Tani, Haritha Mathsyaraja, Marco Campisi, Zehua Li, Koji Haratani, Caroline G. Fahey, Keiichi Ota, Navin R. Mahadevan, Yingxiao Shi, Shin Saito, Kei Mizuno, Tran C. Thai, Nobunari Sasaki, Mizuki Homme, Choudhury Fabliha B. Yusuf, Adam Kashishian, Jipsa Panchal, Min Wang, Benjamin Wolf, Thanh U. Barbie, Cloud P. Paweletz, Prafulla C. Gokhale, David Liu, Ravindra Uppaluri, Shunsuke Kitajima, Jennifer Cain, David A. Barbie - Cancer Discovery 2024 cited by 94

  15. False-Positive Plasma Genotyping Due to Clonal Hematopoiesis

    Authors: Yuebi Hu, Bryan C. Ulrich, Julianna Supplee, Yanan Kuang, Patrick H. Lizotte, Nora Feeney, Nicolas Guibert, Mark M. Awad, Kwok‐Kin Wong, Pasi A. Jänne, Cloud P. Paweletz, Geoffrey R. Oxnard - Clinical Cancer Research 2018 cited by 446

  16. Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia

    Authors: Shruti Bhatt, Marissa S. Pioso, Elyse A. Olesinski, Binyam Yilma, Jeremy Ryan, Thelma Mashaka, Leutz Buon, Sophia Adamia, Haoling Zhu, Yanan Kuang, Abhishek R. Mogili, Abner Louissaint, Stephan Bohl, Annette S. Kim, Anita K. Mehta, Sneha Sanghavi, Youzhen Wang, Erick J. Morris, Ensar Halilovic, Cloud P. Paweletz, David M. Weinstock, Jacqueline S. Garcia, Anthony Letai - Cancer Cell 2020 cited by 174

  17. MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer

    Authors: Shunsuke Kitajima, Tetsuo Tani, Benjamin F. Springer, Marco Campisi, Tatsuya Osaki, Koji Haratani, Minyue Chen, Erik H. Knelson, Navin R. Mahadevan, Jessica Ritter, Ryohei Yoshida, Jens Köhler, Atsuko Ogino, Ryu‐Suke Nozawa, Shriram K. Sundararaman, Tran C. Thai, Mizuki Homme, Brandon Piel, Sophie Kivlehan, Bonje Obua, Connor Purcell, Mamiko Yajima, Thanh U. Barbie, Patrick H. Lizotte, Pasi A. Jänne, Cloud P. Paweletz, Prafulla C. Gokhale, David A. Barbie - Cancer Cell 2022 cited by 101

  18. 3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade

    Authors: Amir Reza Aref, Marco Campisi, Elena V. Ivanova, Andrew Portell, Dalia Larios, Brandon Piel, Natasha Mathur, Chensheng W. Zhou, Raven Vlahos Coakley, Alan Bartels, Michaela Bowden, Zach Herbert, Sarah J. Hill, Sean Gilhooley, Jacob Carter, Israel Cañadas, Tran C. Thai, Shunsuke Kitajima, Valeria Chiono, Cloud P. Paweletz, David A. Barbie, Roger D. Kamm, Russell W. Jenkins - Lab on a Chip 2018 cited by 251

  19. Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC

    Authors: Gonzalo Recondo, Magda Bahcall, Liam F. Spurr, Jianwei Che, Biagio Ricciuti, Giulia C. Leonardi, Ying‐Chun Lo, Yvonne Y. Li, Giuseppe Lamberti, Tom Nguyen, Marina S.D. Milan, Deepti Venkatraman, Renato Umeton, Cloud P. Paweletz, Adem Albayrak, Andrew D. Cherniack, Kristin S. Price, Stephen R. Fairclough, Mizuki Nishino, Lynette M. Sholl, Geoffrey R. Oxnard, Pasi A. Jänne, Mark M. Awad - Clinical Cancer Research 2020 cited by 219

  20. Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC

    Authors: Alissa Keegan, Biagio Ricciuti, Padric M. Garden, Limor Cohen, Reiko Nishihara, Anika E. Adeni, Cloud P. Paweletz, Julianna Supplee, Pasi A. Jänne, Mariano Severgnini, Mark M. Awad, David R. Walt - Journal for ImmunoTherapy of Cancer 2020 cited by 158

  21. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck

    Authors: Glenn J. Hanna, Anne O’Neill, Kee‐Young Shin, Kristine Wong, Vickie Y. Jo, Charles T. Quinn, Jennifer M. Cutler, Michelle Flynn, Patrick H. Lizotte, Donald J. Annino, Laura A. Goguen, Jason Kass, Eleni M. Rettig, Rosh K.V. Sethi, Jochen H. Lorch, Jonathan D. Schoenfeld, Danielle N. Margalit, Roy B. Tishler, Peter C. Everett, Anupam M. Desai, Megan E. Cavanaugh, Cloud P. Paweletz, Ann Marie Egloff, Ravindra Uppaluri, Robert I. Haddad - Clinical Cancer Research 2021 cited by 103

  22. Activation of Tumor-Cell STING Primes NK-Cell Therapy

    Authors: Erik H. Knelson, Elena V. Ivanova, Mubin Tarannum, Marco Campisi, Patrick H. Lizotte, Matthew A. Booker, Ismail Ozgenc, Moataz Noureddine, Brittany Meisenheimer, Minyue Chen, Brandon Piel, Nathaniel Spicer, Bonje Obua, Cameron Messier, Erin Shannon, Navin R. Mahadevan, Tetsuo Tani, Pieter J. Schol, Anna M. Lee-Hassett, Ari Zlota, Ha Vo, Minh Ha, Arrien A. Bertram, Saemi Han, Tran C. Thai, Corinne E. Gustafson, Kartika Venugopal, Timothy J. Haggerty, Thomas P. Albertson, Antja-Voy Hartley, Pınar Ö. Eser, Zehua Li, Israel Cañadas, Marina Vivero, Assunta De Rienzo, William G. Richards, Adnan O. Abu‐Yousif, Vicky A. Appleman, Richard C. Gregory, Alexander Parent, Neil Lineberry, Eric L. Smith, Pasi A. Jänne, Juan J. Miret, Michael Tolstorukov, Rizwan Romee, Cloud P. Paweletz, Raphael Bueno, David A. Barbie - Cancer Immunology Research 2022 cited by 88

  23. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer

    Authors: Geoffrey R. Oxnard, Kenneth S. Thress, Ryan S. Alden, Rachael Lawrance, Cloud P. Paweletz, Mireille Cantarini, James Chih‐Hsin Yang, J. Carl Barrett, Pasi A. Jänne - Journal of Clinical Oncology 2016 cited by 843

  24. EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody–Drug Conjugate HER3–DXd

    Authors: Heidi M. Haikala, Timothy Lopez, Jens Köhler, Pinar O. Eser, Man Xu, Qing Zeng, Tyler J. Teceno, Kenneth Ngo, Yutong Zhao, Elena V. Ivanova, Arrien A. Bertram, Brittaney A. Leeper, Emily S. Chambers, Anika E. Adeni, Luke J. Taus, Mari Kuraguchi, Paul T. Kirschmeier, Channing Yu, Yoshinobu Shiose, Yasuki Kamai, Yang Qiu, Cloud P. Paweletz, Prafulla C. Gokhale, Pasi A. Jänne - Cancer Research 2021 cited by 71